Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/605—Glucagons

Definitions

• the invention relates to compounds having agonist activity at the GIP receptor, and to their use in the treatment of metabolic disorders.
• CVD cardiovascular diseases
• obstructive sleep apnea obstructive sleep apnea
• stroke peripheral artery disease
• microvascular complications CAD
• osteoarthritis CAD
• CVD cardiovascular diseases
• Many have additional cardiovascular risk factors including high/aberrant LDL and triglycerides and low HDL.
• Cardiovascular diseases account for about 50% of the mortality in people with diabetes, and the morbidity and mortality rates relating to obesity and diabetes underscore the medical need for efficacious treatment options.
• GIP Glucose-dependent insulinotropic polypeptide
• gastric inhibitory polypeptide is a 42-residue peptide secreted by enteroendocrine K-cells of the small intestine into the bloodstream in response to oral nutrient ingestion. GIP inhibits the secretion of gastric acid, and it has been shown to be a potent stimulant for the secretion of insulin from pancreatic beta cells after oral glucose ingestion (the "incretin effect") (Creutzfeldt, W., et al, 1979, Diabetologia, 16:75-85).
• GIP and glucagon-like peptide 1 appear to fulfill the requirements to be considered physiological stimulants of postprandial insulin release (Nauck, et al, 1989, J. Clin. Endocrinol Metab., 69:654- 662). It has been shown that the combined effects of GIP and GLP-1 are sufficient to explain the full incretin effect of the enteroinsular axis (Fehmann, H. C, et al, 1989, FEBS Lett, 252: 109-1 12).
• GIP GIP-associated diabetes
• a disease selected from the group consisting of type 1 diabetes, type 2 diabetes (Visboll, T., 2004, Dan. Med. Bull, 51 :364-70), insulin resistance (WO 2005/082928), obesity (Green, B. D., et al, 2004, Current Pharmaceutical Design, 10:3651-3662), metabolic disorder (Gault, V. A., et al, 2003,
• GIP GIP not only enhances insulin secretion acutely, but it also stimulates insulin production through enhancement of proinsulin transcription and translation (Wang, et al, 1996, Mol Cell.
• GIP glycin-1 phosphatidylcholine
• adipose Eckel, et al, 1979, Diabetes, 28: 1 141 -1 142
• muscle O'Harte, et al, 1998, J. Endocrinol, 156:237-243
• inhibition of hepatic glucose production Elahi, D., et al, 1986, Can. J. Physiol. Pharmacol, 65:A18).
• GLP-1 and GIP have additive effects on glycemic control (Gault et al, 201 1 , Clin Sci (Lond); 121 :107-1 17).
• a study by Gault et al showed that sub-chronic co-administration with a GLP-1 analogue, and an acylated GIP analogue resulted in greater glucose-lowering and
• GIP agonists may be particular effective in improving glycaemic control and reducing body weight when they are administered in combination with a GLP-1 receptor agonist (as part of the same
• PCT publication WO 00/58360 discloses peptidyl analogues of GIP which stimulate the release of insulin.
• this application discloses specific peptidyl analogues comprising at least 15 amino acid residues from the N-terminal end of GIP(I -42.
• PCT publication WO 03/082898 discloses C-terminal truncated fragments and N-terminal modified analogues of GIP, as well as various GIP analogues with a reduced peptide bond or alterations of the amino acids close to the DPPFV-specific cleavage site.
• This application further discloses analogues with different linkers between potential receptor binding sites of GIP.
• the compounds of this application are alleged to be useful in treating GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
• tighter control of plasma glucose levels may prevent long-term diabetic complications, thereby providing an improved quality of life for patients.
• GIP may also enhance GLP-1 -mediated body weight loss.
• GIP analogues e.g, PEG(poly ethylene glycol)
• PEG(poly ethylene glycol) has been shown to extent in vivo half-life, but potential side-effects of pegylated pharmaceutical products such as inteferon-beta and ribavirin has been reported (J Clin Gastroenterol. 2004 Sep;38(8):717-22, Cut 2006:55: 1350-1359 doi: 10.1 136/gut.2005.076646).
• the present invention concerns GIP analogues which may have the property of an altered GIP activity, as assessed in in vitro efficacy assays and an altered, preferably increased terminal elimination half-life (T1 ⁇ 2), as assessed in in vivo studies in mice.
• GIP analogues which may have the property of an altered GIP activity, as assessed in in vitro efficacy assays and an altered, preferably increased terminal elimination half-life (T1 ⁇ 2), as assessed in in vivo studies in mice.
• GIP receptor agonists of the present invention are superior to existing GIP analogues because the GIP agonists offer long terminal half-lifes.
• the GIP analogues may thus be used as therapeutics for metabolic disorders including, but not limited to, type 2 diabetes mellitus, obesity and related disorders.
• the invention provides in a first aspect a GIP analogue represented by the general Formula I:
• R 1 is H-, Ac or pGlu pyroglutamic acid (pGlu; (S)-(-)-2-pyrrolidone-5-carboxylic acid), C1-4 alkyl, acetyl, formyl, benzoyl and trifluoroacetyl,
• X2 is Aib, Ala, D-Ala, Gly, Ser, N-Me-Ser, Ac3c, Ac4c or Ac5c;
• X10 is Tyr, Leu or Ser
• X11 is Ser or Leu
• X12 is Lys, ⁇ or lie
• X15 is Asp or Glu
• X16 is Ser, Glu, Lys or ⁇
• X17 is lie, Lys, Gin, Arg or ⁇ ;
• X18 is His, Arg or Ala
• X19 is Gin, Lys, Ala or Glu
• X20 is Gin, Lys, Ala, His or Arg
• X21 is Ala, Leu, Asp or Glu
• X23 is Val or lie
• X24 is Asn or Glu
• X25 is Tyr or Trp
• X27 is Leu, Glu, Ser, Lys or Val
• X28 is Ala, Ser or Arg
• X29 is Aib, Gly, Ala, Gin, Thr, Ser or Lys or is absent;
• Y1 is Lys-Gly, Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro- Ser, Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, Pro-Ser-Ser-Giy-Ala-Pro-Pro-Ser, Gly-Lys-Lys- Asn-Asp-Trp-Lys-His-Asn-lle-Thr-Gln or absent;
• Y2 is ⁇ or is absent
• R 2 is -NH 2 or -OH; wherein ⁇ is a residue independently selected from Lys, Arg, Orn and Cys and wherein the side chain of said residue is conjugated to a lipophilic substituent; and wherein the GIP analogue contains one and only one residue ⁇ ; or a pharmaceutically acceptable salt or solvate thereof.
• R 1 is H-, Ac or pGlu.
• R 1 is H-, Ac or pGlu
• X2 is Aib, Ala, D-Ala or Gly;
• X12 is Lys, ⁇ or lie
• X15 is Asp or Glu
• X16 is Ser, Glu, Lys or ⁇
• X17 is lie, Lys, Gin, Arg or ⁇ ;
• X18 is His, Arg or Ala
• X19 is Gin or Ala
• X20 is Gin, Lys, Ala, His or Arg
• X21 is Ala, Asp or Glu
• X23 is lie or Val
• X24 is Asn or Glu
• X25 is Tyr or Trp
• X27 is Leu, Glu, Ser, Lys or Val
• X28 is Ala, Ser or Arg
• X29 is Aib, Gly, Ala, Gin, Thr, Ser or Lys or is absent;
• Y1 is Lys-Gly , Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-, Giy-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser, Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser, Gly-Lys-Lys-Asn- Asp-Trp-Lys-His-Asn-lle-Thr-Gln or absent;
• Y2 is ⁇ or is absent
• R 2 is -NH 2 or -OH; wherein ⁇ is a Lys residue wherein the side chain of said Lys residue is conjugated to a lipophilic substituent; and wherein the GIP analogue contains one and only one residue ⁇ ; or a pharmaceutically acceptable salt or solvate thereof.
• the invention provides in a further aspect a GIP analogue represented by the general Formula III:
• R is H-, Ac or pGlu
• X15 is Asp or Glu
• X16 is Lys o ⁇
• X17 is He ⁇ ⁇
• X18 is His or Ala
• X19 is Gin or Ala
• X20 is Gin, Lys or Arg
• X21 is Ala, Asp or Glu
• X24 is Asn or Glu
• X25 is Tyr or Trp; X28 is Ala, Ser or Arg;
• X29 is Gin or is absent
• Y1 is Lys-Gly, Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro- Ser, Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, Pro-Ser-Ser-Gly-Ala-Pro-Pro-Ser, Gly-Lys-Lys- Asn-Asp-Trp-Lys-His-Asn-lle-Thr-Gln or absent;
• Y2 is ⁇ or is absent
• R 2 is -NH 2 or -OH; wherein ⁇ is a residue independently selected from Lys, Arg, Orn and Cys and wherein the side chain of said residue is conjugated to a lipophilic substituent; and wherein the GIP analogue contains one and only one residue ⁇ ; or a pharmaceutically acceptable salt or solvate thereof.
• Combinations of residues which may be present at some of the variable positions of Formula III include:
• the GIP-analogue may have the formula R1-Z-R2 where R1 and R2 are as defined above and Z has the sequence:
• the GIP-analogue may have the formula R1-Z-R2 where R1 and R2 are as defined above and Z has the sequence
• the GIP-analogue may be:
• the invention further provides a pharmaceutical composition comprising a GIP analogue as described herein, or a pharmaceutically acceptable salt or solvate thereof, in admixture with a carrier, preferably a pharmaceutically acceptable carrier.
• a GIP analogue may, for example, be a pharmaceutically acceptable acid addition salt.
• the pharmaceutical composition may be formulated as a liquid suitable for administration by injection or infusion.
• the pharmaceutical composition may be formulated to cause controlled, e.g., slow release of said GIP analogue.
• the invention further provides a therapeutic kit comprising a GIP analogue as descibed herein, and a device comprising a GIP analogue as described herein.
• the invention further provides a GIP analogue as described herein, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of medical treatment, e.g. for use in the treatment and/or prevention of a metabolic disorder.
• the invention further provides the use of a GIP analogue as described herein, or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment and/or prevention of a metabolic disorder.
• the invention further provides a method of prevention and or/treatment of a metabolic disorder in a subject, comprising administering a GIP analogue as described herein, or a pharmaceutically acceptable salt or solvate thereof, to the subject.
• the metabolic disorder may be diabetes or a diabetes related disorder, or obesity or an obesity related disorder.
• diabetes or a diabetes related disorder, or obesity or an obesity related disorder.
• the link between obesity and diabetes is well known, so these conditions may be but are not necessarily separate or mutually exclusive.
• Diabetes related disorders include insulin resistance, glucose intolerance, increased fasting glucose, pre-diabetes, type 1 diabetes, type 2 diabetes, gestational diabetes hypertension, dyslipidemia, and combinations thereof. Diabetes related disorders also include atherosclerosis, arteriosclerosis, coronary heart disease, peripheral artery disease and stroke; or conditions associated with atherogenic dyslipidemia, blood fat disorders, elevated blood pressure, hypertension, a prothrombotic state, a proinflammatory state, and bone related disorders such as osteoporosis.
• the blood fat disorder may be selected from high triglycerides, low HDL cholesterol, high LDL cholesterol, and plaque buildup in artery walls, or a combination thereof.
• the prothrombotic state may be selected from high fibrinogen levels in the blood and high plasminogen activator inhibitor-1 levels in the blood.
• the proinflammatory state may be an elevated C-reactive protein level in the blood.
• Obesity related disorders include obesity linked inflammation, obesity linked gallbladder disease and obesity induced sleep apnea, or may be associated with a condition selected from atherogenic dyslipidemia, blood fat disorders, elevated blood pressure, hypertension, a prothrombotic state, and a proinflammatory state, or a combination thereof.
• FIG. 1 Blood glucose levels (A-C) and area under the blood glucose curves (AUC) (D) in an OGTT in 5-hour fasted mice.
• FIG. 2 Blood glucose levels (A-D) and area under the blood glucose curves (AUC) (E) in an OGTT in 5-hour fasted mice.
• the first injection was with vehicle 1 or GLP-1 analogue liraglutide (20 nmol/kg).
• the second injection was with vehicle 2 or Compound 12 (3 and 30 nmol/kg).
• Statistical difference (p ⁇ 0.05) between liraglutide and liraglutide co-treated GIP agonist is shown with a line.
• patient may be used interchangeably and refer to either a human or a non-human animal. These terms include mammals such as humans, primates, livestock animals (e.g., bovines, porcines), companion animals (e.g., canines, felines) and rodents (e.g., mice and rats).
• livestock animals e.g., bovines, porcines
• companion animals e.g., canines, felines
• rodents e.g., mice and rats.
• solvate in the context of the present invention refers to a complex of defined stoichiometry formed between a solute (in casu, a peptide conjugate or pharmaceutically acceptable salt thereof according to the invention) and a solvent.
• the solvent in this connection may, for example, be water, ethanol or another pharmaceutically acceptable, typically small-molecular organic species, such as, but not limited to, acetic acid or lactic acid.
• a solvate is normally referred to as a hydrate.
• agonist refers to a substance (ligand) that activates signaling by the receptor type in question.
• antagonist refers to a substance (ligand) that decreases signaling by the receptor type in question.
• sequences disclosed herein are sequences incorporating an ⁇ -" moiety at the amino terminus (N-terminus) of the sequence, and either an "-OH” moiety or an "-IMH2" moiety at the carboxy terminus (C-terminus) of the sequence.
• the compounds of the present invention have GIP biological activity, in particular in treatment of metabolic diseases such as diabetes and obesity. This can be assessed, e.g., in in vivo assays, in which the blood glucose level or another biological activity is determined after a test animal has been treated or exposed to a GIP analogue.
• the compounds of the present invention may be particular effective in improving glycaemic control and reducing body weight when administered together with a GLP-1 receptor agonist to a diabetic patient and/or an overweight or obese subject. The effect obtained with this combination therapy may be superior to that obtained with the administration of a GLP-1 receptor agonist alone in comparable subjects when given according to a comparable dosing regime.
• the compounds of the present invention may also be capable of improving glycaemic control and reducing bodyweight when administered alone.
• the Y1 and Y2 group has a stabilizing effect on the GIP analogues. Without being bound to any theory it is believed that group comprising the C- terminus part of exendin-4 and GIP compounds has impact on the folding of the peptide.
• the effect of treating with a GIP analogue of the present invention may be superior to that obtained with an equivalent quantity (by mass, or molar ratio) of wild type human GIP in comparable subjects when given according to a comparable dosing regime, alone or in combination with another anti-diabetic or anti-obesity agent.
• Activity in in vitro assays may also be used as a measure of the compounds' activity.
• the compounds typically have activity (i.e. agonist activity) at the GIP receptor (designated GIP-R).
• EC50 values may be used as a numerical measure of agonist potency at a given receptor.
• An EC50 value is a measure of the concentration of a compound required to achieve half of that compound's maximal activity in a particular assay. In any given assay, the EC50 value of a compound in a given assay may be assessed relative to the EC50 of human GIP.
• the ratio of the EC50 value of the test compound to the EC50 value of wild type human GIP (EC5o[test compound] / EC 5 o[GIP]) at the human GIP receptor may be less than 10, less than 5, less than 1 , less than 0.1 , less than 0.05 or less than 0.01.
• EC50 values may be determined using the human GIP receptor assay described in the Examples below. In such an assay, the compounds may, for example, have an EC50 value of 0.001-0.050 nM, 0.001 - 0.030 nM, 0.001-0.020 nM, or 0.001-0.010 nM.
• the compounds typically have minimal or no agonist activity at the GLP-1 receptor.
• the ratio of the EC50 value of the test compound to the EC50 value of the GLP-1 agonist Exendin-4 (ECso[test compound] / EC 5 o[Ex4]) at the human GIP receptor may be at least about 100, at least about 250, at least about 500, at least about 750, at least about 1000, at least about 5000, or at least about 10,000.
• EC50 values may be determined using the human GLP-1 receptor assay described in the Examples below. In such an assay, the compounds may, for example, have an EC50 value of at least 1 nM, at least 3 nM, at least 5 nM or at least 10 nM. Lipophilic group
• the compound of the invention comprises a residue ⁇ , i.e. a residue selected from Lys, Arg, Orn and Cys in which the side chain is conjugated to a lipophilic substituent.
• a residue ⁇ i.e. a residue selected from Lys, Arg, Orn and Cys in which the side chain is conjugated to a lipophilic substituent.
• the substituent binds plasma proteins (e.g. albumin) in the blood stream, thus shielding the compounds of the invention from enzymatic degradation and thereby enhancing the half-life of the compounds. It may also modulate the potency of the compound, e.g. with respect to the GIP receptor.
• the substituent is conjugated to the functional group at the distal end of the side chain from the alpha-carbon.
• the normal ability of the Lys, Arg, Orn or Cys side chain to participate in interactions mediated by that functional group may therefore be reduced or completely eliminated by the presence of the substituent.
• the overall properties of the compound may be relatively insensitive to changes in the actual amino acid present as residue ⁇ . Consequently, it is believed that any of the residues Lys, Arg, Orn and Cys may be present at any position where ⁇ is permitted.
• it may be advantageous that the amino acid component of ⁇ is Lys.
• ⁇ is a residue of Lys, Arg, Orn or Cys in which the side chain is conjugated to a substituent having the formula -Z 1 or -Z 2 -Z 1 .
• -Z 1 is a fatty chain having at a terminus a connection -X- to ⁇ or to Z 2 ;
• -X- is a bond, -CO-, -SO-, or -S0 2 -;
• Z has a polar group at the end of the chain distal from connection -X-; said polar group comprising a carboxylic acid or a carboxylic acid bioisostere, a phosphonic acid, or a sulfonic acid group;
• each Y is independently -NH, -NR, -S or -O, where R is alkyl, a protecting group or forms a linkage to another part of the spacer Z 2 ;
• each X is independently a bond, CO- SO- or SO2-;
• each V is independently a bivalent organic moiety linking Y and X;
• Z 1 is a fatty chain having a connection to ⁇ or to Z 2 , referred to herein as -X-.
• -X- may be, for example, a bond, acyl (-CO-), sulfinyl (-SO-), or sulfonyl (-SO2-).
• -X- is acyl (-CO-), sulfinyl (-SO-), or sulfonyl (-SO2-).
• -X- is acyl (-CO-).
• Z 1 may further have a polar group, said polar group being located at the end of the chain distal from the connection -X-.
• the connection is located at the ⁇ -position with respect to the polar group.
• the polar group may be bound directly to the terminus of the fatty chain, or may be bound via a linker.
• the polar group is an acidic or weakly acid group, for example a carboxylic acid or a carboxylic acid bioisostere, a phosphonate, or a sulfonate.
• the polar group may have a pK a of between -2 and 12 in water, more preferably between 1 and 7, more preferably between 3 and 6.
• Certain preferred polar groups have a pK a of between 4 and 5.
• the polar group may comprise a carboxylic acid (- COOH) or a carboxylic acid bioisostere, a phosphonic acid (-P(0)(OH) 2 ), or a sulfonic acid (- SO2OH) group.
• the polar group if present, comprises a carboxylic acid or carboxylic acid bioisostere.
• Suitable carboxylic acid bioisosteres are known in the art.
• the bioisostere has a proton having a pKa similar to the corresponding carboxylic acid.
• suitable bioisoteres may include, not by way of limitation, tetrazole, acylsulfomides, acylhydroxylamine, and squaric acid derivatives, as shown below (— indicates the point of attachment):
• Fatty chain refers to a moiety comprising a chain of carbon atoms, the carbon atoms being predominantly substituted with hydrogen or hydrogen-like atoms, for example, a hydrocarbon chain.
• Such fatty chains are often referred to as lipophilic, although it will be appreciated that substitution may alter the lipophilic properties of the overall molecule.
• the fatty chain may by aliphatic. It may be entirely saturated or may include one or more double or triple bonds. Each double bond, if present, may be in the E or Z configuration.
• the fatty chain may also have one or more cycloalkylene or heterocycloalkylene moieties in its length, and additionally or alternatively may have one or more arylene or heteroarylene moieties in its length.
• the fatty chain may incorporate a phenylene or piperazinylene moiety in its length as, for example, shown below (wherein— represents the points of attachment within the chain).
• the fatty chain may be derived from a fatty acid, for example, it may be derived from a medium-chain fatty acid (MCFA) with an aliphatic tail of 6-12 carbon atoms, a long-chain fatty acid (LCFA) with an aliphatic tail of 13-21 carbon atoms, or a very long-chain fatty acid
• MCFA medium-chain fatty acid
• LCFA long-chain fatty acid
• LCFA with an aliphatic tail of 22 carbon atoms or more.
• linear saturated fatty acids from which suitable fatty chains may be derived include tridecylic (tridecanoic) acid, myristic (tetradecanoic) acid, pentadecylic (pentadecanoic) acid, palmitic (hexadecanoic) acid, and margaric (heptadecanoic) acid.
• linear unsaturated fatty acids from which suitable fatty chains may be derived include myristoleic acid, palmitoleic acid, sapienic acid and oleic acid.
• the fatty chain may be connected to ⁇ or to Z 2 by an amide linkage, a sulfinamide linkage, a sulfonamide linkage, or by an ester linkage, or by an ether, thioether or amine linkage.
• the fatty chain may have, a bond to ⁇ or to Z 2 or an acyl (-CO-), sulfinyi (-SO-), or sulfonyl (-SO2-) group.
• the fatty chain has a terminus having an acyl (-CO-) group and is connected to ⁇ or Z 2 by an amide or ester linkage.
• Z 1 is a group of formula A-B-Alk-X- wherein
• A is hydrogen or a carboxylic acid, a carboxylic acid bioisostere, a phosphonic acid, or a sulfonic acid group;
• B is a bond or a linker
• X is a bond, acyl (-CO-), sulfinyi (-SO-), or sulfonyl (-SO2-);
• Alk is a fatty chain that may be optionally substituted with one or more substituents.
• the fatty chain is preferably 6 to 28 carbon atoms in length (e.g. a C6-2salkylene), more preferably, 12 to 26 carbons in length (e.g. a Ci 2 -26alkylene), more preferably, 16 to 22 carbons in length (e.g. Ci6-22alkylene), and may be saturated or unsaturated.
• Alk is saturated, that is, preferably Alk is alkylene.
• Optional substituents on the fatty chain may be independently selected from fluoro, Ci-4alkyl, preferably methyl; trifluoromethyl, hydroxymethyl, amino, hydroxyl, preferably methoxy; oxo, and carboxyl, and may be independently located at any point along the chain.
• each optional substituent is selected from fluoro, methyl, and hydroxyl. Where more than one substituent is present, substituents may be the same or different.
• the number of substituents is 0 to 3; more preferably the fatty chain is unsubstituted.
• B may be a bond or a linker.
• B When B is a linker, it may be a cycloalkylene,
• heterocycloalkylene Cearylene, or Cs-6heteroarylene, or C6arylene-0- or C 5 -6heteroarylene- O-.
• B When B is phenylene it may, for example, be selected from 1 ,2-phenylene, 1 ,3-phenylene, 1 ,4-phenylene, preferably 1 ,4-phenylene (so that A-B- is a 4-benzoic acid substituent or 4-benzoic acid bioisostere).
• B When B is phenylene-O- it may, for example, be selected from 1 ,2-phenylene-O- 1 ,3-phenylene-O-, 1 ,4-phenylene-O- preferably 1 ,4-phenylene-O.
• Each phenylene of B may be optionally substituted with one or more substituents selected from fluoro, methyl, trifluoromethyl, amino, hydroxyl, and Ci-4alkoxy, preferably methoxy. It will be appreciated that substituent identity and position may be selected to subtly alter the pK a of the polar group. Suitable inductively or mesomerically electron-withdrawing or donating groups and their positional effects are known in the art.
• B may be Cs-eheteroarylene, for example, pyridinylene or thiofuranylene, and may be optionally substituted as described.
• A-B- may be selected from:
• A is H- or HOOC- and B is a bond.
• A-B-Alk- is an alkyl chain of formula H 3 C-(CH 2 ) n -.
• Z 1 is an acyl group of formula: A-B-Alk-(CO)- or a sulfonyl group of formula:
• Z 1 is an acyl group of formula:
• A is -COOH and B is a bond.
• certain preferred Z 1 are derived from long-chain saturated ⁇ , ⁇ -dicarboxylic acids of formula HOOC-(CH2)i2-22-COOH, preferably, long-chain saturated ⁇ , ⁇ -dicarboxylic acids having an even number of carbon atoms in the aliphatic chain.
• A is H and B is a bond.
• certain preferred Z 1 are derived from long-chain saturated carboxylic acids of formula HOOC-(CH 2 )i 2 -22-CH3, preferably, long-chain saturated carboxylic acids having an even number of carbon atoms in the aliphatic chain.
• Z 1 may be:
• the carboxylic acid group if present, may be replaced by a bioisotere as detailed herein.
• the group Z 2
• Z 2 is an optional spacer that connects Z 1 to the side chain of the amino acid component of ⁇ .
• Z 2 if present, is a spacer bound at one terminus by Y, which may be a nitrogen, oxygen or sulfur atom, and at the other terminus by X, which may be a bond or an acyl (-CO-), sulfinyl (-SO-), sulfonyl (-S02-)or absent.
• Z 2 may be a spacer of formula (— indicate points of attachment):
• Y may be -NH, -NR, -S or -O, where R may be alkyl, a protecting group or may form a linkage to another part of the spacer, with the remaining valency forming a linkage to Z 1 ;
• X may be a bond, CO-, SO-, or SO2-, with the remaining valency forming a linkage to the side chain of the amino acid component of ⁇ ;
• V is a bivalent organic moiety linking Y and X;
• n may be 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10. Where n is 2 or more, each Y, V, and X is independent of every other Y, V, and X.
• Z 2 may be bound at each side by amide, sulfinamide, sulfonamide, or ester linkages or by amino, ether, or thioether linkages depending upon the nature of Y and X and the corresponding linking groups on Z 1 and the side chain.
• each V may also be bound to each adjacent V by linkages as described.
• linkages are amides, esters or sulfonamides, most preferably amides.
• each Y is -NH or -NR and each X is CO- or SO2-. Most preferably, -X- is acyl (-CO-).
• Z 2 is a spacer of formula -S A - -S B - -SA-SB- ⁇ -SB-SA-, wherein S A and SB are as defined below.
• Z 2 is selected from -SA- or -SB-SA- that is, [side chain]-Z 2 Z 1 is [side chain]-S A -Z 1 or [side chain]-S B -S A -Z 1 .
• the group SA is the group SA
• SA may be a single amino acid residue or a residue of an amino acid derivative, especially an amino acid derivative residue having a sulfinyl or sulfonyl in place of the carboxy moiety at the C terminus. Additionally or alternatively, the single amino acid residue may have an oxygen or sulfur atom in place of the nitrogen atom at the N terminus.
• S A may be or may comprise a nitrogen-containing heterocycle, said nitrogen-containing heterocycle being bound within the lipophilic group at one end via a bond, a carboxy, a sulfinyl, or a sulfonyl group and at the other via a ring nitrogen atom.
• SA may comprise a piperazine ring.
• SA is a 5-8-membered heterocycle having 1 or 2 nitrogen atoms and substituted with an X group, where X is a bond, CO- SO-, or SO2-, and where L, if present, is Ci- 4 alkylene (- denotes a point of attachment within the lipophilic group).
• SA is a 6-membered heterocycle having 1 or 2 nitrogen atoms, preferably 2, and substituted with a -CH 2 CO- -CH 2 SO-, or -CH 2 S0 2 - group.
• SA may be:
• SA may be:
• SA is a single amino acid residue or piperazine-1-yl-acetyl. More preferably S A a single amino acid residue.
• the amino acid may be selected from ⁇ -Glu, a-Glu, a-Asp, ⁇ -Asp, Ala, ⁇ -Ala (3-aminopropanoic acid), Dapa (2,3-diaminopropanoic acid), Dab (2,4-diaminobutanoic acid), and Gaba (4-aminobutanoic acid).
• connection may be at any moiety as appropriate. Any carboxylic acid or amino resides not bound within the residue may be free, that is, present as a free carboxylic acid or primary amine, or may be derivatised. Suitable derivatisation is known in the art.
• carboxylic acid moieties may be present in S A amino acid residues as esters, for example, as methyl esters.
• Amino moieties may be present as alkylated amines, for example, methylated, or may be protected as amide or carbamate moieties.
• Other suitable amino acids include ⁇ -Ala (3-aminopropanoic acid) and Gaba (4-aminobutanoic acid) and similar ⁇ amino acids.
• amino acids may be D or L, or a racemic or enantioenriched mixture.
• the amino acid is an L-amino acid.
• the amino acid is a D-amino acid.
• S A has a carboxylic acid substituent, with ⁇ -Glu, a-Glu, a- Asp, and ⁇ -Asp, and sulfinyl and sulfonyl derivatives thereof, being preferred.
• the amino acid residue is:
• -X- is -CO-, -SO-, -SO2-, preferably -CO-, and a is 1 or 2, preferably 2.
• the carboxylic acid is an ester, and the amino acid residue is:
• R is Ci- 4 alkyl or Cearyl.
• R is Ci- 4 alkyl, preferably methyl or ethyl, more preferably ethyl.
• a preferred SA group bearing a carboxylic acid is ⁇ -Glu.
• SA is selected from Dapa or ⁇ -Glu. Most preferably, SA is ⁇ -Glu.
• each polymeric unit Pu may be bound at each side by amide, sulfinamide, sulfonamide, or ester linkages or by amino, ether, or thioether linkages depending upon the nature of Y and X and the corresponding linking groups on Z SA, and Lys.
• each Pu may be independently a unit of formula: wherein:
• Y may be -NH, -NR, -S or -O, wherein R may be alkyl, a protecting group or may form a linkage to another part of the spacer, with the remaining valency forming a linkage to Z 1 ;
• X may be a bond, CO- SO-, or SO2-, with the remaining valency forming a linkage to the ⁇ side chain;
• V is a bivalent organic moiety linking Y and X.
• V is the a-carbon of a natural or unnatural amino acid, that is V is - CHR AA - wherein R AA is an amino acid side chain; or V is an optionally substituted
• Ci-ealkylene, or V is a chain comprising one or more units of ethylene glycol in series, also known as PEG chain, for example, -CH2CH2-(OCH 2 CH2)m-0-(CH2)p- where m is 0, 1 , 2, 3, 4, or 5, and p is 1 , 2, 3, 4, or 5; when X is CO-, p is preferably 1 , 3, 4, or 5.
• Optional alkylene substituents include fluoro, methyl, hydroxy, hydroxymethy, and amino.
• Preferred Pu units include:
• SB may comprise one or more of each of Pu', Pu", and Pu"' in any order, or may comprise one or more units of Pu', Pu", and Pu"' only, or one of more units selected from Pu' and Pu", Pu' and Pu'", or Pu" and Pu'".
• Each Pu' may be independently selected from any natural or unnatural amino acid residue and, for example, may be selected from Gly, Pro, Ala, Val, Leu, lie, Met, Cys, Phe, Tyr, Trp, His, Lys, Arg, Gin, Asn, a-Glu, ⁇ -Glu, Asp, Ser Thr, Dapa, Gaba, Aib, ⁇ -Ala, 5- aminopentanoyl, 6-aminohexanoyl, 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, and 10-aminodecanoyl.
• Pu' amino acid residues are selected from Gly, Ser, Ala, Thr, and Cys, more preferably from Gly and Ser.
• SB is -(Pu')n-, wherein n is 1 to 8, more preferably 5 to 7, most preferably 6.
• SB is -(Pu')n-, n is 6 and each Pu' is independently selected from Gly or Ser, with a preferred sequence being -Gly-Ser-Gly-Ser- Gly-Gly-. (ii).
• Pu dipeptide residues
• Each Pu'' may be independently selected from any dipeptide residue comprising two natural or unnatural amino acid residues bound by an amide linkage.
• Preferred Pu" dipeptide residues include Gly-Gly, Gly-Ser, Ser-Gly, Gly-Ala, Ala-Gly, and Ala-Ala, more preferably Gly-Ser and Gly-Gly.
• SB is -( ⁇ '%-, wherein n is 2 to 4, more preferably 3, and each Pu" is independently selected from Gly-Ser and Gly-Gly.
• SB is - ( ⁇ ") ⁇ -, n is 3 and each Pu" is independently selected from Gly-Ser and Gly-Gly, with a preferred sequence being -(Gly-Ser)-(Gly-Ser)-(Gly-Gly).
• Amino acids having stereogenic centres within Pu' and Pu" may be racemic, enantioenriched, or enantiopure.
• the or each amino acid is independently an L-amino acid.
• the or each amino acid is independently a D-amino acid.
• Each Pu'" ma be independently a residue of general formula:
• m is 0, 1 , 2, 3, 4, or 5, preferably 1 or 2
• p is 1 , 3, 4, or 5, preferably 1.
• m is 1 and p is 1 , that is, Pu'" is a residue of 8-amino-3,6- dioxaoctanoic acid (also known as ⁇ 2-[2-aminoethoxy]ethoxy ⁇ acetic acid and H2N-PEG 3 - COOH). This residue is referred to herein as -PEG 3 -
• PEG chains are also known in the art.
• 11-amino-3,6,9- trioxaundecanoic acid also known as H2N-PEG4-COOH or -PEG4-.
• SB is -(Pu'")n- wherein n is 1 to 3, more preferably 2.
• S B is -PEG3-PEG3-.
• the GIP analogue compounds employed in the context of the invention may provide an attractive treatment option for metabolic diseases including obesity, diabetes mellitus
• the GIP analogue compounds of the present invention may be particular effective in improving glycaemic control and reducing body weight when they are administered in combination with a GLP- receptor agonist (as part of the same pharmaceutical formulation or as separate formulations).
• Glucagon-like peptide-1 receptor agonists also known as GLP-1 receptor agonists or incretin mimetics are agonists of the GLP-1 receptor.
• GLP-1 receptor agonists or incretin mimetics are agonists of the GLP-1 receptor.
• GLP-1 agonists include but are not limited to exenatide (Byetta®/Bydureon®), liraglutide (Victoza®), semaglutide, lixisenatide (Lyxumia®), albiglutide (Tanzeum®) and Taspoglutide.
• Diabetes comprises a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Diabetes is classified into type 1 diabetes, type 2 diabetes and gestational diabetes on the basis on pathogenic characteristics. Type 1 diabetes accounts for 5-10% of all diabetes cases and is caused by auto-immune destruction of insulin-secreting pancreatic ⁇ -cells. Acute signs of diabetes include excessive urine production, resulting compensatory thirst and increased fluid intake, blurred vision, unexplained weight loss, lethargy, and changes in energy metabolism. However, in type 2 diabetes symptoms are often not severe or may be absent. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of various organs, notably the eyes, kidneys, nerves, heart and blood vessels.
• Type 2 diabetes accounts for 90-95% of diabetes cases and is a result of a complex set of metabolic disorders. However, symptoms are often not severe or may be absent. Type 2 diabetes is the consequence of endogenous insulin production becoming insufficient to maintain plasma glucose levels below diagnostic thresholds.
• Gestational diabetes refers to any degree of glucose intolerance identified during pregnancy.
• Pre-diabetes includes impaired fasting glucose and impaired glucose tolerance and refers to those states that occur when blood glucose levels are elevated but below the levels that are established for the clinical diagnosis for diabetes.
• a large proportion of people with type 2 diabetes and pre-diabetes are at increased risk of morbidity and mortality due to the high prevalence of additional metabolic risk factors, including abdominal obesity (excessive fat tissue around the abdominal internal organs), atherogenic dyslipidemia (blood fat disorders including high triglycerides, low HDL cholesterol and/or high LDL cholesterol, which foster plaque buildup in artery walls), elevated blood pressure (hypertension) a prothrombotic state (e.g. high fibrinogen or plasminogen activator inhibitor- 1 in the blood), and/or a proinflammatory state (e.g., elevated C-reactive protein in the blood).
• abdominal obesity excessive fat tissue around the abdominal internal organs
• atherogenic dyslipidemia blood fat disorders including high triglycerides, low HDL cholesterol and/or high LDL cholesterol, which foster plaque buildup in artery walls
• elevated blood pressure hypertension
• a prothrombotic state e.g. high fibrinogen or plasminogen activator inhibitor- 1 in the blood
• obesity confers an increased risk of developing pre-diabetes, type 2 diabetes as well as, e.g., certain types of cancer, obstructive sleep apnea and gall-bladder disease.
• Dyslipidemia is associated with increased risk of cardiovascular disease.
• High Density Lipoprotein (HDL) is of clinical importance since an inverse correlation exists between plasma HDL concentrations and risk of atherosclerotic disease.
• the majority of cholesterol stored in atherosclerotic plaques originates from LDL and hence an elevated concentration of Low Density Lipoproteins (LDL) is closely associated with atherosclerosis.
• LDL Low Density Lipoproteins
• the HDL/LDL ratio is a clinical risk indictor for atherosclerosis and coronary atherosclerosis in particular.
• the GIP analogues of the present invention may be used as pharmaceutical agents for preventing weight gain, promoting weight loss, reducing excess body weight or treating obesity (e.g., by control of appetite, feeding, food intake, calorie intake, and/or energy expenditure and lipoiysis), including morbid obesity, as well as associated diseases and health conditions including but not limited to obesity linked inflammation, obesity linked gallbladder disease and obesity induced sleep apnea.
• the GIP analogues employed in the context of the invention may also be used for treatment of insulin resistance, glucose intolerance, pre-diabetes, increased fasting glucose, type 2 diabetes, hypertension, dyslipidemia (or a combination of these metabolic risk factors), atherosclerosis,
• arteriosclerosis arteriosclerosis
• coronary heart disease peripheral artery disease
• stroke arteriosclerosis
• peripheral artery disease arteriosclerosis
• stroke peripheral artery disease
• these all conditions which may be associated with obesity.
• the effects of the compounds employed in the context of the invention on these conditions may be mediated in whole or in part via an effect on body weight, or may be independent thereof.
• the GIP analogues of the present invention may thus be used for the treatment and/or prevention of any of the diseases, disorders, or conditions described herein, including insulin resistance, glucose intolerance, increased fasting glucose, pre-diabetes, type 1 diabetes, type 2 diabetes, gestational diabetes hypertension, dyslipidemia, or a combination thereof.
• the diabetes related disorder is selected from atherosclerosis, arteriosclerosis, coronary heart disease, peripheral artery disease and stroke; or associated with a condition selected from atherogenic dyslipidemia, blood fat disorders, elevated blood pressure, hypertension, a prothrombotic state, and proinflammatory state, or a combination thereof.
• the blood fat disorder is selected from high triglycerides, low HDL cholesterol, high LDL cholesterol, plaque buildup in artery walls, or a combination thereof.
• the prothrombotic state is selected from high fibrinogen levels in the blood and high plasminogen activator inhibitor-1 levels in the blood.
• the proinflammatory state is an elevated C-reactive protein level in the blood.
• the obesity related disorder is selected from obesity linked inflammation, obesity linked gallbladder disease and obesity induced sleep apnea.
• the GIP analogues of the present invention may also be used for the treatment and/or prevention of any of the diseases, disorders, or conditions associated with diabetes related osteoporosis including increased risk of bone fractures (Khazai N.B. et al, 2009, Current Opinion in Endocrinology, Diabetes and Obesity, vol. 16, no. 6, 435-445).
• the increase in fracture risk is likely to be related to impaired bone quality rather than to bone mineral density.
• the related mechanisms, due at least in part to hyperglycemia, neuropathy, and higher incidence of hypovitaminosis D, are not yet fully understood (Takiishi T et al, 2010,
• the invention also provides a therapeutic kit comprising a GIP analogue (e.g., GIP agonist compound) of the present invention, optionally in combination with a pharmaceutically acceptable carrier.
• a GIP analogue e.g., GIP agonist compound
• the invention provides a device comprising a GIP analogue of the invention for delivery of the GIP analogue to a subject.
• the GIP analogues (e.g., GIP agonist compounds) of the present invention, or salts or solvates thereof, may be formulated as pharmaceutical compositions prepared for storage or administration, which typically comprise a therapeutically effective amount of a compound employed in the context of the invention, or a salt or solvate thereof, in a pharmaceutically acceptable carrier.
• the pharmaceutical composition is formulated as a liquid suitable for administration by injection or infusion, or which is formulated to cause slow release of the GIP analogue.
• the therapeutically effective amount of a compound of the present invention will depend, e.g., on the route of administration, the type of mammal being treated, and the physical characteristics of the specific mammal under consideration. These factors and their relationship to determining this amount are well known to skilled practitioners in the medical arts. This amount and the method of administration can be tailored to achieve optimal efficacy, and may depend on such factors as weight, diet, concurrent medication and other factors, well known to those skilled in the medical arts. The dosage sizes and dosing regimen most appropriate for human use may be guided by the results obtained by the present invention, and may be confirmed in properly designed clinical trials.
• An effective dosage and treatment protocol may be determined by conventional means, starting with a low dose in laboratory animals and then increasing the dosage while monitoring the effects, and systematically varying the dosage regimen as well. Numerous factors may be taken into consideration by a clinician when determining an optimal dosage for a given subject. Such considerations are known to the skilled person.
• pharmaceutically acceptable carrier includes any of the standard pharmaceutical carriers.
• Pharmaceutically acceptable carriers for therapeutic use are well known in the
• Suitable pH buffering agents may be, e.g., phosphate, citrate, acetate, lactate, maleate,
• TriS tris/hydroxymethyl)aminomethane
• TAPS A/-Tris(hydroxymethyl)methyl-3- aminopropanesulphonic acid
• ammonium bicarbonate diethanolamine
• histidine which in certain embodiments is a preferred buffer, arginine, lysine, or acetate or mixtures thereof.
• the term further encompasses any agents listed in the US Pharmacopeia for use in animals, including humans.
• salts refers to a salt of the compound. Salts include pharmaceutically acceptable salts, such as, e.g., acid addition salts and basic salts.
• Examples of acid addition salts include hydrochloride salts, citrate salts and acetate salts.
• Examples of basic salts include salts where the cation is selected from alkali metals, such as sodium and potassium, alkaline earth metals such as calcium, and ammonium ions
• R 3 and R 4 independently designate optionally substituted Ci-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted aryl, or optionally substituted heteroaryl.
• R 3 and R 4 independently designate optionally substituted Ci-6-alkyl, optionally substituted C2-6-alkenyl, optionally substituted aryl, or optionally substituted heteroaryl.
• Other examples of pharmaceutically acceptable salts are described in
• Treatment is an approach for obtaining beneficial or desired clinical results.
• beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
• Treatment may also mean prolonging survival as compared to expected survival if not receiving treatment.
• Treatment is an intervention performed with the intention of preventing the development or altering the pathology of a disorder. Accordingly, “treatment” refers to both therapeutic treatment and prophylactic or preventative measures in certain embodiments. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. By treatment is meant inhibiting or reducing an increase in pathology or symptoms (e.g. weight gain, hyperglycemia) when compared to the absence of treatment, and is not necessarily meant to imply complete cessation of the relevant condition.
• pathology or symptoms e.g. weight gain, hyperglycemia
• compositions of the invention may be in unit dosage form.
• the composition is divided into unit doses containing appropriate quantities of the active component.
• the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules.
• the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms. It may be provided in single dose injectable form, for example in the form of an injection pen.
• Compositions may be formulated for any suitable route and means of administration.
• Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, and
• transdermal administration may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
• Subcutaneous or transdermal modes of administration may be particularly suitable for certain of the compounds described herein.
• Combination therapy may be particularly suitable for certain of the compounds described herein.
• a GIP- analogue employed in the context of the invention may be administered as part of a combination therapy with at least one other agent for treatment of diabetes, obesity, dyslipidemia, or hypertension.
• the at least two active agents may be given together or separately, and as part of the same pharmaceutical formulation or as separate formulations.
• the GIP analogue employed in the context of the invention (or the salt or solvate thereof) may be used in combination with an antidiabetic agent including but not limited to a glucagon-like peptide receptor 1 agonist, metformin, a sulfonylurea, a glinide, a DPP-IV inhibitor, a glitazone, or insulin.
• the compound or salt or solvate thereof is used in
• the compound or salt or solvate thereof is used in combination with insulin or an insulin analogue for achieving adequate glycemic control.
• insulin analogues include but are not limited to Lantus®, NovoRapid®, Humalog®, NovoMix®, Actraphane HM®, Levemir® and Apidra®.
• the GIP analogue or salt or solvate thereof may further be used in combination with one or more of an anti-obesity agent, including but not limited to a glucagon- like peptide receptor 1 agonist, peptide YY or analogue thereof, cannabinoid receptor 1 antagonist, lipase inhibitor, melanocortin receptor 4 agonist, or melanin concentrating hormone receptor 1 antagonist.
• an anti-obesity agent including but not limited to a glucagon- like peptide receptor 1 agonist, peptide YY or analogue thereof, cannabinoid receptor 1 antagonist, lipase inhibitor, melanocortin receptor 4 agonist, or melanin concentrating hormone receptor 1 antagonist.
• the GIP analogue or salt or solvate thereof may be used in combination with an anti-hypertension agent, including but not limited to an angiotensin- converting enzyme inhibitor, angiotensin II receptor blocker, diuretics, beta-blocker, or calcium channel blocker.
• an anti-dyslipidemia agent including but not limited to a statin, a fibrate, a niacin and/or a cholesterol absorption inhibitor.
• a nucleic acid molecule may encode the amino acid sequence of any of Formula I to III or a precursor thereof.
• the amino acid sequence encoded can be regarded as a precursor of a compound of the invention.
• nucleic acid sequences will be provided as expression constructs wherein the encoding nucleic acid is in functional linkage with appropriate control sequences to direct its expression.
• the expression construct may be provided in the context of a host cell capable of expressing (and optionally also secreting) the amio acid precursor, or ina cell-free expression system.
• the invention provides a method of producing a GIP analogue of the invention, the method comprising expressing an amino acid precursor of the GIP analogue and modifying the precursor to provide the GIP analogue.
• the modification may comprise chemical modification of a Lys, Arg or Cys residue present at position 17 to introduce the lipophilic moiety, modification of the N- or C- terminus, and/or modification of any other amino acid side chains in the molecule (e.g. to introduce a non-naturally occurring amino acid residue).
• the compounds of the invention may also be manufactured by standard peptide synthetic methods, e.g. by standard solid-phase or liquid-phase methodology, either stepwise or by fragment assembly, and isolating and purifying the final peptide compound product, or by any combinations of recombinant and synthetic methods.
• GIP analogues that exhibit signaling selectivity, and methods for screening these compounds.
• Signaling selectivity may be, for example, preferential pathway activation or preferential pathway inhibition, or both.
• the analogue administered alone or in
• combination with a GLP-1 agonist may be useful for the treatment and/or prevention of diseases or conditions caused or characterized by excess body weight, including, but not limited to, obesity, morbid obesity, obesity linked inflammation, obesity linked gallbladder disease, obesity induced sleep apnea, metabolic syndrome, pre-diabetes, insulin resistance, glucose intolerance, type 2 diabetes, type I diabetes, hypertension, atherogenic
• dyslipidaemia atherosclerosis, arteriosclerosis, coronary heart disease, peripheral artery disease, and stroke or microvascular disease.
• Fmoc-Lys(ivDde)-OH or alternatively another amino acid with an orthogonal side chain protective group was introduced at the position of the acylation.
• the N-terminal of the peptide backbone was then Boc-protected using Boc20 or alternatively by using a Boc-protected amino acid in the last coupling. While the peptide was still attached to the resin, the orthogonal side chain protective group was selectively cleaved using freshly prepared hydrazine hydrate (2-4%) in NMP for 2 x 15 min.
• the unprotected lysine side chain was first coupled with Fmoc-Glu-OtBu or another spacer amino acid, which was deprotected with piperidine and acylated with a lipophilic moiety using the peptide coupling methodology as described above.
• COMU l-[(l-(cyano-2-ethoxy-2-oxoethylideneaminooxy)-dimethylamino- morpholinomethylene)]methanaminium hexaflourophosphate
• ivDde 1 -(4,4-dimethyl-2,6-dioxocyclohexylidene)3-methyl-butyl
• DIPEA diisopropylethylamine
• HATU A/-[(dimethylamino)-1 H-1 ,2,3-triazol[4,5-b]pyhdine-1 -ylmethylene]-/V- methylmethanaminium hexafluorophosphate ⁇ /oxide
• the resin was washed with EtOH (3 x 10 ml) and Et.20 (3 x 0 ml) and dried to constant weight at room temperature (r.t.).
• the crude peptide was cleaved from the resin by treatment with TFA/TIS/water (95/2.5/2.5; 40 ml, 2 h; r.t.). Most of the TFA was removed at reduced pressure and the crude peptide was precipitated and washed three times with diethylether and dried to constant weight at room temperature.
• the crude peptide was purified to greater than 90% by preparative reverse phase HPLC using a PerSeptive Biosystems VISION Workstation equipped with a C-18 column (5 cm; 10 pm) and a fraction collector and run at 35 ml/min with a gradient of buffer A (0.1% TFA, aq.) and buffer B (0.1 % TFA, 90% MeCN, aq.). Fractions were analyzed by analytical HPLC and MS and relevant fractions were pooled and lyophilized. The final product was characterized by HPLC and MS.
• Lys17 was incorporated as Fmoc-Lys(Dde)-OH for orthogonal coupling.
• the first 9 amino acids and amino acid number 24 (counting from the C-terminal) was double couple meaning the building block was coupled twice before deprotection.
• Boc- Tyr(tBu)-OH was incorporated as the final building block in the N-terminal.
• Piperidine/DMF (20%; 10 ml) was added to the resin for initial deprotection and the mixture was heated by microwaves (30 sec; 40°C).
• the reaction vessel was drained and a second portion of piperidine/DMF (20%; 10 ml) was added and heated (75°C; 3 min.) again.
• the resin was then washed with DMF (6 x 10 ml).
• the orthogonal side chain protective group was selectively cleaved using freshly prepared hydrazine hydrate (2-4%) in NMP for 2 x 15 min.
• the unprotected lysine side chain was first coupled with Fmoc-Glu-OtBu and the two Peg3 buildingblocks using standard coupling and deprotection conditions as explained above.
• the lipophilic moiety was incorporated as a 19-carboxy-nonadecanoic acid mono tert butyl ester again using standard coupling conditions.
• HEK293 cells expressing the human GIP R stable cell lines generated through transfection of the cDNA for human GIP R and selection of stable clones were seeded at 30,000 cells/well in 96-well microtiter plates coated with 0.01 % poly-L-lysine, and grown for 1 day in culture in 200 ⁇ growth medium (DMEM, 10% FCS, Penicillin (100 Ill/ml), Streptomycin (100 pg/ml)).
• Results were converted into cAMP concentrations using a cAMP standard curve prepared in KRBH buffer containing 0.1% (v/v) DMSO. The resulting cAMP curves were plotted as absolute cAMP concentrations (nM) over log (test compound concentration) and analyzed using the curve fitting program XLfit.
• Table 2 EC50 average values of the compounds on the GIP-R compared to control peptide.
• GIP R human GIP receptor
• GLP-1R human GLP-1 receptor
• HEK293 cells expressing the GIP R or the GLP-1 R stable cell lines generated through transfection of expression vector containing the cDNA for the receptor in question and selection of stable clones were seeded at 30,000 cells/well in 96-well microtiter plates coated with 0.01 % poly-L-lysine, and grown for 1 day in culture in 200 ⁇ growth medium (DMEM, 10% FCS, Penicillin (100 lU/ml), Streptomycin (100 pg/ml)).
• the cAMP response was normalized relative to a positive and negative control (reference agonist (0.1 nM human GIP or 1 nM Exendin-4) and assay buffer, respectively) to calculate the EC50 and maximal response from the concentration response curve using 4 parameter logistic (4PL) nonlinear regression model for curve fitting.
• Table 2a EC50 average values of the compounds compared to control peptides.
• mice Males with a body weight of approximately 25 g were given either a single subcutaneous (s.c.) bolus or a single intravenous (i.v.) bolus of each peptide to be tested.
• s.c. subcutaneous
• i.v. intravenous
• the dosing vehicle was a phosphate buffer containing mannitol (pH 7.5).
• mice were included for each compound and each administration route.
• the mice were euthanized immediately after blood sampling by cervical dislocation.
• Plasma samples were analyzed after solid phase extraction (SPE) or protein precipitation followed by liquid chromatography mass
• mice Male C57BL/6J (JAX) mice (Charles River, UK) fed high-fat diet (45% of total energy from fat, D12451 Research Diet Inc.) for approximately 4 months were used.
• mice Male C57BL/6J mice (Charles River, Germany) fed high-fat diet (60% of total energy from fat, DIO Rodent Purified 58Y1 - 58126 from TestDiet) for approximately 5 months were used.
• mice were thereafter treated once daily with two separate s.c. injections (5 mL/kg of each injection) from day 0 to day 27.
• the first injection was with vehicle 1 (25 mM phosphate, 125 mM sodium chloride buffer, pH 7.4) or GLP-1 analogue liraglutide (20 nmol/kg).
• the second injection was with vehicle 2 (25 mM phosphate, 205 mM D-Mannitol, pH 7.5) or GIP agonist (30 and/or 300 nmol/kg).
• the GIP agonist was only dosed every third day of the study (starting on day 0). On other days, GIP agonist was replaced with vehicle 2. The daily injections were given in the morning (at 9.00-10.00).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Endocrinology (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Diabetes (AREA)
• Toxicology (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Epidemiology (AREA)
• Hematology (AREA)
• Immunology (AREA)
• Obesity (AREA)
• Physical Education & Sports Medicine (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Vascular Medicine (AREA)
• Child & Adolescent Psychology (AREA)
• Urology & Nephrology (AREA)
• Emergency Medicine (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (16)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (2)

Family

ID=58766442

Family Applications (1)

Country Status (13)

Cited By (23)

Families Citing this family (3)

Family Cites Families (175)

• 2015
  • 2015-10-29 US US15/521,631 patent/US10253078B2/en active Active
  • 2015-10-29 RU RU2017114175A patent/RU2716985C2/ru active
  • 2015-10-29 CA CA2965732A patent/CA2965732A1/en active Pending
  • 2015-10-29 DK DK15794490.1T patent/DK3212218T3/da active
  • 2015-10-29 EP EP15794490.1A patent/EP3212218B1/en active Active
  • 2015-10-29 JP JP2017522910A patent/JP6898231B6/ja active Active
  • 2015-10-29 CN CN201580059529.3A patent/CN107001439B/zh active Active
  • 2015-10-29 MX MX2017005457A patent/MX381640B/es unknown
  • 2015-10-29 WO PCT/EP2015/075120 patent/WO2016066744A2/en not_active Ceased
  • 2015-10-29 TW TW104135658A patent/TWI705973B/zh active
  • 2015-10-29 AU AU2015340586A patent/AU2015340586B2/en active Active
  • 2015-10-29 KR KR1020177014449A patent/KR102620911B1/ko active Active
  • 2015-10-29 ES ES15794490T patent/ES2883345T3/es active Active
  • 2015-10-29 EP EP21175659.8A patent/EP3985016A1/en active Pending
• 2019
  • 2019-02-21 US US16/281,347 patent/US11001619B2/en active Active
• 2021
  • 2021-04-02 US US17/221,287 patent/US11814417B2/en active Active
  • 2021-06-08 JP JP2021096014A patent/JP7312215B2/ja active Active
• 2023
  • 2023-07-07 JP JP2023112456A patent/JP7541600B2/ja active Active
  • 2023-09-22 US US18/371,680 patent/US20240209054A1/en active Pending

Also Published As

Similar Documents

Legal Events